Cancer Ongoing 2020 North Shore NSW


Investigate the activity and safety of adding Lu-PSMA to enzalutamide in patients with metastatic castrate resistant prostate cancer (mCRPC) not previously treated with chemotherapy.

Trial overview

Prostate cancer
Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer.
Eligibility criteria
  • Metastatic Castration Resistant Prostate Cancer not previously treated in that setting
  • Rising PSA
  • High risk for early failure on enzalutatmide
Study details

Eligibility will be assessed based on screening GaPSMA PET and FDG PET. Once eligible you will be randomised to enzaluatamide alone or enzalutamide with LuPSMALuPSMA is a nuclear medicine targeted therapy. While on treatment there will be regular blood tests and scans to monitor progress. At completion of treatment the study will continue to follow your progress.

Further information

For more information regarding this clinical trial click here.


North Shore NSW